Why These Biotech Stocks Have Been on Investors' Radar? - Juno Therapeutics, Immunomedics, Ultragenyx Pharma, and Intercept Pharma

May 25, 2016, 08:10 ET from Chelmsford Park SA

NEW YORK, May 25, 2016 /PRNewswire/ --

The Biotech arena may not be in its best shape right now, but this does not mean investors are sidelining stocks in this space. Here are today's ActiveWallSt.com highlights: Juno Therapeutics Inc. (NASDAQ: JUNO), Immunomedics Inc. (NASDAQ: IMMU), Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), and Intercept Pharmaceuticals Inc. (NASDAQ: ICPT). Get the free access these stocks' technical alerts by clicking below:


At the close on Tuesday, shares in Juno Therapeutics Inc., a biopharma Company, which engages in developing cell-based cancer immunotherapies, gained 0.47%, ending the day at $40.38. The stock recorded a trading volume of 762,812 shares. The Company's shares have advanced 18.80% in the previous three months. The stock is trading above its 50-day moving average by 0.97%. Moreover, shares of Juno Therapeutics have a Relative Strength Index (RSI) of 55.42. Register now and access free trade alerts on JUNO at:


Shares in Immunomedics Inc., the New Jersey headquartered clinical-stage biopharma Company, ended the day 1.90% higher at $4.29. A total volume of 2.34 million shares was traded, which was above their three months average volume of 1.03 million shares. In the last month and the previous three months, the stock has surged 30.79% and 103.32%, respectively. Additionally, the Company's shares have advanced 39.74% since the start of this year. The stock is trading above its 50-day and 200-day moving averages by 36.67% and 66.84%, respectively. Furthermore, shares of Immunomedics have an RSI of 72.79. Visit us today and activate your complimentary trade alerts on IMMU at:


On Tuesday, shares in Ultragenyx Pharmaceutical Inc. finished 4.74% higher at $68.28. A total volume of 696,474 shares was traded, which was above their three months average volume of 598,150 shares. The Company focuses on the identification, acquisition, development, and commercialization of various products for the treatment of rare and ultra-rare genetic diseases in the U.S. The stock has advanced 8.83% in the previous three months. The Company's shares are trading above their 50-day moving average by 5.59%. Additionally, Ultragenyx Pharmaceutical's stock has an RSI of 59.57. Trade alert on RARE is available for free at:


New York-based biopharma Company, Intercept Pharmaceuticals Inc.'s stock recorded a trading volume of 298,822 shares at the end of yesterday's session and closed the day at $139.80, gaining 0.87%. The stock has advanced 24.32% in the previous three months. The Company's shares are trading above their 50-day moving average by 0.83%. Additionally, shares of Intercept Pharmaceuticals have an RSI at 53.15. Complimentary alert on ICPT is accessible at:



Active Wall Street: 

Active Wall Street (AWS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. AWS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

AWS has not been compensated; directly or indirectly; for producing or publishing this document. 


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@activewallst.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by AWS. AWS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  


AWS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. AWS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, AWS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither AWS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.activewallst.com

CONTACT For any questions, inquiries, or comments reach out to us directly at: Office Address: 3rd floor, 207 Regent Street, London, W1B 3HH, United Kingdom Email: info@activewallst.com Phone number:  1-858-257-3144 CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Chelmsford Park SA